CN115443271A - Chk1抑制剂的合成方法 - Google Patents

Chk1抑制剂的合成方法 Download PDF

Info

Publication number
CN115443271A
CN115443271A CN202180027747.4A CN202180027747A CN115443271A CN 115443271 A CN115443271 A CN 115443271A CN 202180027747 A CN202180027747 A CN 202180027747A CN 115443271 A CN115443271 A CN 115443271A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
impurities
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027747.4A
Other languages
English (en)
Chinese (zh)
Inventor
M.施维伯
T.罗斯纳
D.赵
R.米勒
R.杜利纳
M.胡莫拉
S.E.戈特施林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sierra Oncology Inc
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Priority to CN202510460667.8A priority Critical patent/CN120441567A/zh
Publication of CN115443271A publication Critical patent/CN115443271A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180027747.4A 2020-04-07 2021-04-06 Chk1抑制剂的合成方法 Pending CN115443271A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510460667.8A CN120441567A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006305P 2020-04-07 2020-04-07
US63/006,305 2020-04-07
PCT/US2021/025977 WO2021207210A1 (en) 2020-04-07 2021-04-06 Methods for synthesis of chk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510460667.8A Division CN120441567A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Publications (1)

Publication Number Publication Date
CN115443271A true CN115443271A (zh) 2022-12-06

Family

ID=78024095

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180027747.4A Pending CN115443271A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法
CN202510460667.8A Pending CN120441567A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510460667.8A Pending CN120441567A (zh) 2020-04-07 2021-04-06 Chk1抑制剂的合成方法

Country Status (8)

Country Link
US (1) US12606550B2 (https=)
EP (1) EP4132922A4 (https=)
JP (1) JP2023523165A (https=)
CN (2) CN115443271A (https=)
BR (1) BR112022020278A2 (https=)
CA (1) CA3174222A1 (https=)
TW (1) TW202204348A (https=)
WO (1) WO2021207210A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2005011597A2 (en) 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
CN1243033C (zh) 2004-07-15 2006-02-22 合肥工业大学 一种通过内增韧制备薄膜级聚l－乳酸共聚物的方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2604284A1 (en) 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP5052518B2 (ja) 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9000027B2 (en) 2008-02-04 2015-04-07 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8865726B2 (en) * 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
WO2013103836A2 (en) 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CN102675858A (zh) 2012-05-22 2012-09-19 同济大学 一种具有形状记忆功能可降解泪管栓塞的制备方法
GB201316526D0 (en) 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
WO2015176033A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3347026A4 (en) 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
JP7273791B2 (ja) 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
CA3065803A1 (en) 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3092079A1 (en) 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors
CA3135165A1 (en) 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
MX2021013905A (es) 2019-05-14 2022-05-18 Sierra Oncology Inc Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302635A (zh) * 2012-05-15 2015-01-21 癌症研究技术有限公司 5-[[4-[[吗啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈及其治疗应用

Also Published As

Publication number Publication date
TW202204348A (zh) 2022-02-01
EP4132922A1 (en) 2023-02-15
WO2021207210A1 (en) 2021-10-14
CN120441567A (zh) 2025-08-08
US20230150994A1 (en) 2023-05-18
BR112022020278A2 (pt) 2022-12-06
JP2023523165A (ja) 2023-06-02
CA3174222A1 (en) 2021-10-14
EP4132922A4 (en) 2024-07-03
US12606550B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
US11261161B2 (en) Processes for preparing ASK1 inhibitors
KR20180005248A (ko) 복소환형 화합물의 합성
AU2020207953A1 (en) Bruton's tyrosine kinase inhibitors
CN115443271A (zh) Chk1抑制剂的合成方法
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3，4-二氢-1，4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
TWI547485B (zh) 取代吡唑啉羧酸脒衍生物的合成
CN110759923B (zh) 嘧啶并吡咯并哒嗪衍生物、其中间体、制备方法、药物组合物和用途
HK40104000A (en) Processes for preparing ask1 inhibitors
HK40045362B (zh) 制备ask1抑制剂的方法
HK40114080A (zh) 制备取代的吡唑并嘧啶的方法
EP3906235A1 (en) Method for preparing sulfonamides drugs
TW202235076A (zh) 製備（９Ｓ）—Ｎ—［３—（６—甲基嘧啶—４—基)—３—氮雜雙環［３。２。１］辛—８—基］—９—（２，３，４—三氟苯基)—６，７，８，９—四氫—５Ｈ—［１，２，４］三唑并［１，５—ａ］吖呯—２—胺的方法及其固體形式
HK40035686A (en) Processes for preparing ask1 inhibitors
HK1246275B (en) Processes for preparing ask1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20221206